Pioglitazone may reduce cardiovascular risk in adults with type 2 diabetesBMJ 2006; 333 doi: https://doi.org/10.1136/bmj.333.7580.1212 (Published 07 December 2006) Cite this as: BMJ 2006;333:1212
Pioglitazone is an antidiabetic drug that works by reducing insulin resistance. It may also help reduce the risk of cardiovascular disease in adults with type 2 diabetes, according to a recent randomised trial.
The trial was based in Chicago and …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial